Akebia extends Chief Legal Officer's departure date to March 29, 2024, with possible further extension

Akebia Therapeutics, Inc.

Nicole R. Hadas, SVP, Chief Legal Officer and Corporate Secretary, will now separate on March 29, 2024 (previously October 6, 2023).
Under certain conditions, termination date may extend to September 22, 2024.
This is the fourth amendment to the original May 2022 retention and separation agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nicole R. Hadas

Senior Vice President, Chief Legal Officer and Corporate Secretary

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-03-29
Filed: October 12, 2023, 7:59 PM ET

On October 6, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to March 29, 2024, unless the Company and Ms. Hadas agree to an earlier termination date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole R. Hadas departed as Senior Vice President, Chief Legal Officer and Corporate Secretary at Akebia Therapeutics, Inc..

Action: separated
Role: Senior Vice President, Chief Legal Officer and Corporate Secretary

Exact text from the filing

On October 6, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to March 29, 2024, unless the Company and Ms. Hadas agree to an earlier termination date.

View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-23-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.